Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Nasdaq Real Time Price USD

AstraZeneca PLC (AZN)

Compare
73.57
+0.73
+(1.00%)
As of 9:35:05 AM EDT. Market Open.
Loading Chart for AZN
  • Previous Close 72.84
  • Open 73.70
  • Bid 63.35 x 100
  • Ask 84.03 x 100
  • Day's Range 73.57 - 73.78
  • 52 Week Range 62.75 - 87.68
  • Volume 208,631
  • Avg. Volume 5,476,025
  • Market Cap (intraday) 228.091B
  • Beta (5Y Monthly) 0.16
  • PE Ratio (TTM) 32.70
  • EPS (TTM) 2.25
  • Earnings Date Apr 29, 2025
  • Forward Dividend & Yield 1.55 (2.13%)
  • Ex-Dividend Date Feb 21, 2025
  • 1y Target Est 85.19

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

www.astrazeneca.com

94,300

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AZN

View More

Performance Overview: AZN

Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

AZN
13.80%
FTSE 100 (^FTSE)
6.15%

1-Year Return

AZN
9.99%
FTSE 100 (^FTSE)
9.09%

3-Year Return

AZN
20.37%
FTSE 100 (^FTSE)
16.09%

5-Year Return

AZN
94.35%
FTSE 100 (^FTSE)
57.45%

Compare To: AZN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AZN

View More

Valuation Measures

As of 3/27/2025
  • Market Cap

    223.49B

  • Enterprise Value

    248.07B

  • Trailing P/E

    32.37

  • Forward P/E

    16.47

  • PEG Ratio (5yr expected)

    1.04

  • Price/Sales (ttm)

    4.21

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    4.59

  • Enterprise Value/EBITDA

    16.07

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.01%

  • Return on Assets (ttm)

    7.88%

  • Return on Equity (ttm)

    17.59%

  • Revenue (ttm)

    54.07B

  • Net Income Avi to Common (ttm)

    7.03B

  • Diluted EPS (ttm)

    2.25

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.53B

  • Total Debt/Equity (mrq)

    74.53%

  • Levered Free Cash Flow (ttm)

    8.46B

Research Analysis: AZN

View More

People Also Watch